Design, Synthesis, and Biological Evaluation of Androgen Receptor (AR) Antagonist-Heat Shock Protein 90 (Hsp90) Inhibitor Conjugates for Targeted Therapy of Castration-Resistant Prostate Cancer

Androgen deprivation in cases of castration-resistant prostate cancer (CRPC) leads to adverse effects, including loss of muscle and bone mass and gain of subcutaneous fat. The tumor specific suppression of androgen receptor (AR) signaling, while not global, may reduce side effects. We present a class of small molecular conjugates consisting of an AR antagonist linked to a heat shock protein 90 (Hsp90) inhibitor. We demonstrate that the high accumulation of Hsp90 on the surface of CRPC cells allows uptake of conjugates and increases the enrichment of drugs in the tumor cells. After penetrating prostate cancer cells, the conjugates not only inhibit AR function by the antagonist component but also bind to Hsp90 and suppress the AR protein level. Compared to AR antagonists, these conjugates showed improved tumor-targeting ability and enhanced potency against Enzalutamide-resistant 22Rv1 cells.

Automated summary

Androgen deprivation in castration-resistant prostate cancer can have adverse effects, but tumor-specific suppression of androgen receptor signaling may reduce side effects. This study presents a new class of small molecular conjugates that can target prostate cancer cells and suppress AR function by binding to Hsp90. These conjugates showed improved tumor-targeting ability and enhanced potency against Enzalutamide-resistant cells.